Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | PRKCQ | Q04759 | 11/20 | 0.55 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.43 |
| ▸ | MERTK | Q12866 | 2/20 | 0.43 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11746290 | 0.88 | L3MBTL1 (0.62) | L3MBTL1PRKCQSTK17ASIRT5GSK3B | |
| SCHEMBL12876603 | 0.88 | L3MBTL1 (0.70) | L3MBTL1PRKCQSTK17ASIRT5GSK3B | |
| SCHEMBL4191611 | 0.85 | L3MBTL1 (0.66) | L3MBTL1PRKCQSTK17ASIRT5ALDH1A1 | |
| SCHEMBL5975211 | 0.85 | L3MBTL1 (0.52) | L3MBTL1PRKCQSTK17ASIRT5ALDH1A1 | |
| SCHEMBL11676466 | 0.82 | L3MBTL1 (0.58) | L3MBTL1PRKCQSTK17ASIRT5ALDH1A1 | |
| SCHEMBL12876599 | 0.81 | L3MBTL1 (0.71) | L3MBTL1PRKCQSTK17AALDH1A1MAPT | |
| SCHEMBL5408700 | 0.80 | STK17A (0.80) | L3MBTL1PRKCQSTK17AGSK3BMAPT | |
| SCHEMBL5419910 | 0.77 | STK17A (0.63) | L3MBTL1PRKCQSTK17AGSK3BMAPT | |
| SCHEMBL1194029 | 0.76 | STK17A (0.49) | STK17ASIRT5FLT3TYRO3MERTK | |
| SCHEMBL9041749 | 0.75 | MAPT (0.59) | L3MBTL1PRKCQSTK17AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185562-B1 | PYRROLOPYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-02 | — | — | EP | disclosed |
| US-8318731-B2 | Pyrrolopyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-27 | — | — | US | disclosed |
| US-20100204197-A1 | PYRROLOPYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
| EP-2185562-A1 | PYRROLOPYRIMIDINES | Janssen Pharmaceutica, N.V. (BE) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016132-A1 | PYRROLOPYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204197-A1 | PYRROLOPYRIMIDINES | PLK4, PLK2, PLK3 | L3MBTL1 3049/4885PRKCQ 371/4885STK17A 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.